An interview with Thierry Diagana, Head of the Novartis Institute for Tropical Diseases.

Novartis researchers are searching for more effective ways to discover drugs for neurological and psychiatric diseases.

A researcher in South Africa investigating a rare skin disease was losing hope of a breakthrough. Then she made a discovery.

All treatments that exist today started with patients volunteering to participate in a study and healthcare professionals offering their expertise.

Collaborations are driving advances in sickle cell disease research, bringing new hope to patients.

Talk to any cancer researcher or doctor today and what you hear is wonder and hope.

The best treatment for multifaceted diseases like NASH may be combinations of drugs.

Novartis is betting on both human inquisitiveness and computer expertise to harness the wealth of its digital research and development platform, data42.

Novartis immunologist describes the excitement of discovering a promising new immuno-oncology (IO) target in the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).

New Global Head of Cardiovascular and Metabolic Diseases Research looks to apply new tools to address tough challenges.